Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study
Abstract
The aim of this study is to evaluate longitudinal change in plasma neurofilament light (NF-L) and tau levels in relationship to clinical and radiological measures in professional fighters. Participants (active and retired professional fighters and control group) underwent annual blood sampling, 3-Tesla magnetic resonance imaging (MRI) brain imaging, computerized cognitive testing, and assessment of exposure to traumatic brain injury. Plasma tau and NF-L concentrations were measured using Simoa assays. Multiple linear regression models were used to compare the difference across groups in regard to baseline measurements, whereas mixed linear models was used for the longitudinal data with multiple measurements for each participant. Plasma samples were available on 471 participants. Baseline NF-L measures differed across groups (F3,393 = 6.99; p = 0.0001), with the active boxers having the highest levels. Higher NF-L levels at baseline were correlated with lower baseline MRI regional volumes and lower cognitive scores. The number of sparring rounds completed by the active fighters was correlated with NF-L (95% confidence interval, 0.0116–0.4053; p = 0.0381), but not tau, levels. Among 126 subjects having multiple yearly samples, there was a significant difference in average yearly percentage change in tau across groups (F3,83 = 3.87; p = 0.0121). We conclude that plasma NF-L and tau behave differently in a group of active and retired fighters; NF-L better reflects acute exposure whereas the role of plasma tau levels in signifying chronic change in brain structure over time requires further study.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
McKee A.C., Cantu R.C., Nowinski C.J., Hedley-Whyte E.T., Gavett B.E., Budson A.E., Santini VE, Lee H.S., Kublius C.A., and Stern R.A. (2009). Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 68, 709–735.
2.
DeKosky S.T., Blennow K., Ikonomovic M.D., and Gandy S. (2013). Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat. Rev. Neurol. 9, 192–200.
3.
Zetterberg H., and Blennow K. (2016). Fluid biomarkers for mild traumatic brain injury and related disorders. Nat. Rev. 12, 563–574.
4.
Shahim P., Tegner Y., Wilson D.H., Randall J., Skillbäck T., Pazooki D., Kallberg B., Blennow K., and Zetterberg H. (2014). Blood biomarkers for brain injury in concussed professional hockey players. JAMA Neurol. 71, 684–692.
5.
Neselius S., Brisby H., Theodorrson A., Blennow K., Zetterberg H., and Marcusson J. (2012). CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 7, e33606.
6.
Shahim P., Zetterberg H., Tegner Y., and Blennow K. (2017). Serum neurofilament light as a biomarker for mild traumatic brain injury in contact sports. Neurology 88, 1788–1794.
7.
Olivera A., Lejbman N., Jeromin A., French L.M., Kim H.S., Cashion A., Mysliwiec V., Diaz-Arrastia R., and Gill J. (2015). Peripheral total tau in military personnel who sustain traumatic brain injuries during deployment. JAMA Neurol. 72, 1109–1116.
8.
Shahim P., Tegner Y., Gustafsson B., Gren M., Arlig J., Olsson M., Lehto N., Engstrom A., Hoglund K., Portelius E., Zetterberg H., and Blennow K. (2016). Neurochemical aftermath of repetitive head traumatic brain injury. JAMA Neurol. 73, 1308–1315.
9.
Rojas J.C., Karydas A., Bang J., Tsai R.M., Blennow K., Liman V., Kramer J.H., Rosen H., Miller B.L., Zetterberg H., and Boxer A.L. (2016). Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann. Clin. Transl. Neurol. 3, 216–225.
10.
Lu C.H., Macdonald-Wallis C., Gray E., Pearce N., Petzold A., Norgren N., Giovannoni G., Frattia P., Sidle K., Fish M., Orrell R., Howard R., Talbot K., Greensmith L., Kuhle J., Turner M.R., and Malaspina A. (2015). Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84, 2247–2257.
11.
Mattsson N., Andreasson U., Zetterberg H., and Blennow K. (2017). Association of plasma neurofilament light with neurodegernation in patients with Alzheimer's disease. JAMA Neurol. 74, 557–566.
12.
Bernick C., Banks S., Phillips M., Lowe M., Shin W., Obuchowski N., Jones S., and Modic M. (2013). Professional fighters brain health study: rationale and methods. Am. J. Epidemiol. 178, 280–286.
13.
Gualtieri C.T., and Johnson L.G. (2006). Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch. Clin. Neuropsychol. 2, 623–643.
14.
Bernick C., Banks S.J., Shin W., Obuchowski N., Butler S., Noback M., Phillips M., Lowe M., Jones S., and Modic M. (2015). Repeated head trauma is associated with smaller thalamic volumes and slower processing speed: the Professional Fighters' Brain Health Study. Br. J. Sports Med. 49, 1007–1011.
15.
Mishra V.R., Zhuang X., Sreenivasan K.R., Banks S.J., Yang Z., Bernick C., and Cordes D. (2017). Multimodal MR imaging signatures of cognitive impairment in active professional fighters. Radiology 285, 555–567.
16.
Rohrer J.D., Woollacott I.O., Dick K.M., Brotherhood E., Gordon E., Fellows A., Toombs J., Druyeh R., Cardoso M.J., Ourselin S., Nicholas J.M., Norgren N., Mead S., Andreasson U., Blennow K., Schott J.M., Fox N.C., Warren J.D., and Zetterberg H. (2016). Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329–1336.
17.
Mattsson N., Zetterberg H., Janelidze S., Insel P.S., Andreasson U., Stromrud E., Palmqvist S., Bakeer D., Tan Hehir C.A., Jeromin A., Hanlon D., Song L., Shaw L.M., Trojanowski J.Q., Weiner M.W., Hansson O., and Blennow K. (2016). Plasma tau in Alzheimer disease. Neurology 87, 1827–1835.
18.
Shan G., and Gerstenberger S. (2017). Fisher's exact approach for post hoc analysis of a chi-squared test. PLoS One 12, e0188709.
19.
Skillback T., Farahmand B., Bartlett J.W., Rosén C., Mattsson N., Nägga K., Kilander L., Religa D., Wimo A., Winblad B., Rosengren L., Schott J.M., Blennow K., Eriksdotter M., and Zetterberg H (2014) CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology 83, 1945–1953.
20.
Friede R.L., and Samorajski T. (1970). Axon calibre related to neurofilaments and miocrotubules in sciatic nerve fibers of rats and mice. Anat. Rec. 167, 379–387.
21.
Trojanowski J.Q., Schuck T., Schmidt M.L., and Lee V.M. (1989). Distribution of tau proteins in the normal human central and peripheral nervous system. J. Histochem. Cytochem. 37, 209–215.
22.
Blennow K., de Leon M.J., and Zetterberg H. (2006). Alzheimer's disease. Lancet 368, 387–403.
23.
Kuhle J., Barro C., Andreasson U., Derfuss T., Lindberg R., Sandelius Å., Liman V., Norgren N, Blennow K., and Zetterberg H. (2016). Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 54, 1655–1661.
24.
Zetterberg H., Wilson D., Andreasson U., Minthon L., Blennow K., Randall J., and Hansson O. (2013). Plasma tau levels in Alzheimer's disease. Alzheimers Res. Ther. 5, 9.
25.
Oliver J., Jones M., Anzalone A., Kirk K.M., Gable D.A., Repshas J.T., Johnson T.A., Höglund K., Blennow K., and Zetterberg H. (2017). A season of American football is not associated with plasma tau levels. J. Neurotrauma 34, 3295–3300.
26.
Bishop C.A., Newbould R.D., Lee J.S., Honeyfield L., Quest R., Colasanti A., Ali R., Mattoscio M., Cortese A., Nicholas R., Matthews P.M., Muraro P.A., and Waldman AD. (2016). Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions. Neuroimage Clin. 13, 9–15.
27.
Rubenstein R., Chang B., Yue J., Chiu A., Winkler E.A., Puccio A.M., Diaz-Arrastia R., Yuh E.L., Mukherjee P., Valadka A.B., Gordon W.A., Okonkwo D.O., Davies P., Agarwal S., Lin F., Sarkis G., Yadikar H., Yang Z., Manley G.T., Wang K.K.W.; and the TRACK-TBI Investigators, Cooper S.R., Dams-O'Connor K., Borrasso A.J., Inoue T., Maas A.I.R., Menon D.K., Schnyer D.M., and Vassar M.J. (2017). Comparing plasma phospho tau, total tau, and phospho tau-total tau ratio as acute and chronic traumatic brain injury biomarkers. JAMA Neurol. 74, 1063–1072.
28.
Stern R., Tripodis Y., Baugh C., Fritts N.G., Martin B.M., Chaisson C., Cantu R.C., Joyce J.A., Shah S., Ikezu T., Zhang J., Gercel-Taylor C., and Taylor D.D. (2016). Preliminary study of plasma exosomal tau as a potential biomarker for chronic traumatic encephalopathy. J Alzheimers Dis 51:1099–1109
29.
Morris M., Maeda S., Vossel K., and Mucke L. (2011). The many faces of tau. Neuron 70, 410–426.
30.
Disanto G., Barro C., Benkert Naegelin Y., Schädelin S., Giardiello A., Zecca C., Blennow K., Zetterberg H., Leppert D., Kappos L., Gobbi C., andKuhle J.; Swiss Multiple Sclerosis Cohort Study Group. (2017). Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870.
31.
Ljungqvist J., Zetterberg H., and Mitsis M. (2017). Serum neurofilament light protein as a marker for diffuse axonal injury: results from a case series study. J. Neurotrauma 34, 1124–1127.
Information & Authors
Information
Published In
Journal of Neurotrauma
Volume 35 • Issue Number 20 • October 15, 2018
Pages: 2351 - 2356
PubMed: 29609512
Copyright
Copyright 2018, Mary Ann Liebert, Inc., publishers.
History
Published in print: October 15, 2018
Published online: 1 October 2018
Published ahead of print: 11 July 2018
Published ahead of production: 2 April 2018
Topics
Authors
Author Disclosure Statement
Charles Bernick receives funding support for the Professional Fighters Brain Health Study from UFC, Bellator/Spike TV, Haymon Boxing, Top Rank Promotions, and UCLA Dream fund; he has been a speaker for Allergan pharmaceuticals. Henrik Zetterberg has served at advisory board meetings for Eli Lilly and Roche Diagnostics; has received travel support from TEVA; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. Kaj Blennow has served as a consultant or at advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Pfizer, and Roche Diagnostics and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Venture-based platform company at the University of Gothenburg.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.